Treatment of adult-onset still’s disease: A review

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2014, Pages 33-43

  Jamilloux, Yvan ^a,b   Gerfaud Valentin, Mathieu ^a   Henry, Thomas ^a   Sève, Pascal ^a  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Adult onset Still s disease; Anakinra; Canakinumab; Tocilizumab; Treatment

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CANAKINUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENZYME; ETANERCEPT; IMMUNOGLOBULIN; INDOMETACIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TOCILIZUMAB;

ADULT ONSET STILL DISEASE; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; HEADACHE; HEMOPHAGOCYTIC SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNE RESPONSE; INFECTION; INFUSION RELATED REACTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LEUKOPENIA; LUNG HEMORRHAGE; MYOCARDITIS; PLASMAPHERESIS; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; THROMBOCYTOPENIC PURPURA; TIME TO TREATMENT; TREATMENT DURATION;

EID: 84919783186     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S64951     Document Type: Review

References (112)

1. Bywaters EG. Still’s disease in the adult. Ann Rheum Dis. 1971;30(2): 121-133.
2. Still GF. On a form of chronic joint disease in children. Med Chir Trans. 1897;80:47-60
3. Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still’s disease. Ann Rheum Dis. 2006;65(5):564-572.
4. Tanaka S, Matsumoto Y, Ohnishi H, et al. [Comparison of clinical features of childhood and adult onset Still’s disease]. Ryu¯machi Rheum. 1991;31(5):511-518. Japanese.
5. Uppal SS, Pande IR, Kumar A, et al. Adult onset Still’s disease in northern India: comparison with juvenile onset Still’s disease. Br J Rheumatol. 1995;34(5):429-434.
6. Luthi F, Zufferey P, Hofer MF, So AK. “Adolescent-onset Still’s disease”: characteristics and outcome in comparison with adult-onset Still’s disease. Clin Exp Rheumatol. 2002;20(3):427-430.
7. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19(3): 424-430.
8. Fautrel B, Zing E, Golmard J-L, et al. Proposal for a new set of classification criteria for adult-onset Still disease. Medicine. 2002;81(3):194-200.
9. Mahroum N, Mahagna H, Amital H. Diagnosis and classification of adult Still’s disease. J Autoimmun. 2014;48-49:34-37.
10. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still’s disease. Autoimmun Rev. 2014;13(7):708-722.
11. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297.
12. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell. 2010;140(6):784-790.
13. Maria AT, Le Quellec A, Jorgensen C, Touitou I, Rivière S, Guilpain P. Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. August 27, 2014. [Epub ahead of print].
14. Canna SW. Editorial. Interferon-γ: friend or foe in systemic juvenile idiopathic arthritis and adult Still’s disease. Arthritis Rheumatol. 2014; 66(5):1072-1076.
15. Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine. 2013;61(2):345-348.
16. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset Still disease: manifestations, treatments, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93(2):91-99.
17. Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum. 2010;62(8): 2530-2535.
18. Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014; 66(6):1405-1413.
19. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545-555.
20. Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66(4):1034-1043.
21. Moulis G, Sailler L, Astudillo L, Pugnet G, Arlet P. May anakinra be used earlier in adult onset Still disease? Clin Rheumatol. 2010; 29(10):1199-1200.
22. DeWitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res. 2012;64(7):1001-1010.
23. Pay S, Türkçapar N, Kalyoncu M, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25(5):639-644.
24. Nagashima T, Iwamoto M, Matsumoto K, Minota S. Interleukin-18 in adult-onset Still’s disease: treatment target or disease activity indicator? Intern Med. 2012;51(4):449.
25. Kim H-A, Sung J-M, Suh C-H. Therapeutic responses and prognosis in adult-onset Still’s disease. Rheumatol Int. 2012;32(5):1291-1298.
26. Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70(2):118-136.
27. Mitamura M, Tada Y, Koarada S, et al. Cyclosporin A treatment for Japanese patients with severe adult-onset Still’s disease. Mod Rheumatol. 2009;19(1):57-63.
28. Nakamura H, Odani T, Shimizu Y, Takeda T, Kikuchi H. Usefulness of tacrolimus for refractory adult-onset Still’s disease: report of six cases. Mod Rheumatol. 2014;18:1-5.
29. Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still’s disease. J Rheumatol. 1999;26(2):373-378.
30. Vignes S, Wechsler B, Amoura Z, et al. Intravenous immunoglobulin in adult Still’s disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 1998;16(3):295-298.
31. Permal S, Wechsler B, Cabane J, Perrot S, Blum L, Imbert JC. [Treatment of Still’s disease in adults with intravenous immunoglobulins]. Rev Med Interne. 1995;16(4):250-254. French.
32. Emmenegger U, Frey U, Reimers A, et al. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol. 2001;68(1):4-10.
33. Liozon E, Ly K, Aubard Y, Vidal E. Intravenous immunoglobulins for adult Still’s disease and pregnancy. Rheumatology. 1999;38(10): 1024-1025.
34. Gerfaud-Valentin M, Hot A, Huissoud C, Durieu I, Broussolle C, Seve P. Adult-onset Still’s disease and pregnancy: about ten cases and review of the literature. Rheumatol Int. 2014;34(6):867-871.
35. Lequerré T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67(3):302-308.
36. Benucci M, Li GF, Del Rosso A, Manfredi M. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still’s disease: the first case report. Clin Exp Rheumatol. 2005;23(5):733.
37. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727-735.
38. Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum. 2002;46(5):1171-1176.
39. Cavagna L, Caporali R, Epis O, Bobbio-Pallavicini F, Montecucco C. Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol. 2001;19(3):329-332.
40. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis. 2001;60 Suppl 3:iii55-iii57.
41. Kokkinos A, Iliopoulos A, Greka P, Efthymiou A, Katsilambros N, Sfikakis PP. Successful treatment of refractory adult-onset Still’s disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol. 2004;23(1):45-49.
42. Fautrel B, Sibilia J, Mariette X, Combe B, Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64(2):262-266.
43. Aikawa NE, Ribeiro AC, Saad CG, et al. Is anti-TNF switching in refractory Still’s disease safe and effective? Clin Rheumatol. 2011; 30(8):1129-1134.
44. Kaneko K, Kaburaki M, Muraoka S, et al. Exacerbation of adult-onset Still’s disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration. Int J Rheum Dis. 2010; 13(4):e67-e69.
45. Agarwal S, Moodley J, Ajani Goel G, Theil KS, Mahmood SS, Lang RS. A rare trigger for macrophage activation syndrome. Rheumatol Int. 2011; 31(3):405-407.
46. Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still’s disease successfully treated with anakinra. Ann Rheum Dis. 2005;64(4):647-648.
47. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. 2005;52(6):1794-1803.
48. Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN. Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007;66(6):842-843.
49. Kötter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007;37(3):189-197.
50. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res Ther. 2011;13(3):R91.
51. Rudinskaya A, Trock DH. Successful treatment of a patient with refractory adult-onset Still disease with anakinra. J Clin Rheumatol. 2003; 9(5):330-332.
52. Nordström D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol. 2012;39(10):2008-2011.
53. Lo Gullo A, Caruso A, Pipitone N, Macchioni P, Pazzola G, Salvarani C. Canakinumab in a case of adult onset Still’s disease: efficacy only on systemic manifestations. Joint Bone Spine. 2014;81(4):376-377.
54. Kontzias A, Efthimiou P. The use of canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still’s disease. Semin Arthritis Rheum. 2012;42(2):201-205.
55. Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64(2):557-567.
56. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396-2406.
57. Swart JF, Barug D, Möhlmann M, Wulffraat NM. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Ther. 2010;10(12):1743-1752.
58. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747-754.
59. Puéchal X, DeBandt M, Berthelot J-M, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res. 2011;63(1):155-159.
60. Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol. 2014;33(1):49-55.
61. Elkayam O, Jiries N, Dranitzki Z, et al. Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol. 2014;41(2):244-247.
62. Ortiz-Sanjuán F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014;66(6):1659-1665.
63. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385-2395.
64. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998-1006.
65. Cush JJ, Medsger TA Jr, Christy WC, Herbert DC, Cooperstein LA. Adult-onset Still’s disease. Clinical course and outcome. Arthritis Rheum. 1987;30(2):186-194.
66. Wouters JM, van de Putte LB. Adult-onset Still’s disease; clinical and laboratory features, treatment and progress of 45 cases. Q J Med. 1986;61(235):1055-1065.
67. Kong X-D, Xu D, Zhang W, Zhao Y, Zeng X, Zhang F. Clinical features and prognosis in adult-onset Still’s disease: a study of 104 cases. Clin Rheumatol. 2010;29(9):1015-1019.
68. Kim YJ, Koo BS, Kim Y-G, Lee C-K, Yoo B. Clinical features and prognosis in 82 patients with adult-onset Still’s disease. Clin Exp Rheumatol. 2014;32(1):28-33.
69. Koizumi R, Tsukada Y, Ideura H, Ueki K, Maezawa A, Nojima Y. Treatment of adult Still’s disease with dexamethasone, an alternative to prednisolone. Scand J Rheumatol. 2000;29(6):396-398.
70. Hot A, Toh M-L, Coppéré B, et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients. Medicine (Baltimore). 2010;89(1):37-46.
71. Pavy S, Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73(4):388-395.
72. Chen D-Y, Lan J-L, Lin F-J, Hsieh T-Y. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31(11):2189-2198.
73. Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still’s disease. Association with chronic articular disease. Rheumatology. 2001;40(12):1398-1404.
74. Ichida H, Kawaguchi Y, Sugiura T, et al. Clinical manifestations of adult-onset Still’s disease presenting with erosive arthritis: association with low levels of ferritin and IL-18. Arthritis Care Res (Hoboken). October 7, 2013. [Epub ahead of print].
75. Shimizu M, Yokoyama T, Yamada K, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology. 2010;49(9):1645-1653.
76. Gattorno M, Piccini A, Lasigliè D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008; 58(5):1505-1515.
77. Pouchot J, Arlet J-B. Biological treatment in adult-onset Still’s disease. Best Pract Res Clin Rheumatol. 2012;26(4):477-487.
78. Lin Y-T, Wang C-T, Gershwin ME, Chiang B-L. The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev. 2011;10(8):482-489.
79. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7(7):416-426.
80. Arlet J-B, Le TH, Marinho A, et al. Reactive haemophagocytic syndrome in adult-onset Still’s disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006;65(12):1596-1601.
81. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13(4):289-298.
82. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34(5):1133-1138.
83. Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of adult-onset Still’s disease. Clin Rheumatol. 2014;33(3):305-314.
84. Silva CA, Silva CH, Robazzi TC, et al. [Macrophage activation syndrome associated with systemic juvenile idiopathic arthritis]. J Pediatr (Rio J). 2004;80(6):517-522. Portuguese.
85. Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003;30(2):401-403.
86. Tristano AG. Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Monit. 2008;14(3):RA27-RA36.
87. Mizrahi M, Ben-Chetrit E. Relapsing macrophage activating syndrome in a 15-year-old girl with Still’s disease: a case report. J Med Case Rep. 2009;3:138.
88. Pamuk ON, Pamuk GE, Usta U, Cakir N. Hemophagocytic syndrome in one patient with adult-onset Still’s disease. Presentation with febrile neutropenia. Clin Rheumatol. 2007;26(5):797-800.
89. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4(11):615-620.
90. Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011;17(1):23-27.
91. Record JL, Beukelman T, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol. 2011;38(1):180-181.
92. Stern A, Riley R, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still’s disease after initiation of etanercept therapy. J Clin Rheumatol. 2001;7(4):252-256.
93. Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21(1):92-96.
94. Aellen P, Raccaud O, Waldburger M, Chamot AM, Gerster JC. [Still’s disease in adults with disseminated intravascular coagulation]. Schweiz Rundsch Med Prax. 1991;80(15):376-378. German.
95. Arai Y, Handa T, Mitani K. [Adult-onset Still disease presenting with disseminated intravascular coagulation]. Rinsho Ketsueki. 2004;45(4):316-318. Japanese.
96. Park J-H, Bae JH, Choi Y-S, et al. Adult-onset Still’s disease with disseminated intravascular coagulation and multiple organ dysfunctions dramatically treated with cyclosporine A. J Korean Med Sci. 2004;19(1):137-141.
97. Yokoyama M, Suwa A, Shinozawa T, et al. [A case of adult onset Still’s disease complicated with adult respiratory distress syndrome and disseminated intravascular coagulation]. Nihon Rinsho Meneki Gakkai Kaishi. 1995;18(2):207-214. Japanese.
98. Mori T, Tanigawa M, Iwasaki E, et al. [Cyclosporine therapy of adult onset Still’s disease with disseminated intravascular coagulation]. Nihon Rinsho Meneki Gakkai Kaishi. 1993;34(2):147-152. Japanese.
99. Matsumoto K, Nagashima T, Takatori S, et al. Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab. Clin Rheumatol. 2009;28(4):485-487.
100. Gerfaud-Valentin M, Sève P, Iwaz J, et al. Myocarditis in adult-onset Still disease. Medicine. (Baltimore). 2014; 93(17): 280-289
101. Perez MG, Rodwig FR Jr. Chronic relapsing thrombotic thrombocytopenic purpura in adult onset Still’s disease. South Med J. 2003;96(1):46-49.
102. Masuyama A, Kobayashi H, Kobayashi Y, et al. A case of adult-onset Still’s disease complicated by thrombotic thrombocytopenic purpura with retinal microangiopathy and rapidly fatal cerebral edema. Mod Rheumatol. 2013;23(2):379-385
103. Sayarlioglu M, Sayarlioglu H, Ozkaya M, Balakan O, Ucar MA. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome and adult onset Still’s disease: case report and review of the literature. Mod Rheumatol. 2008;18(4):403-406
104. Onundarson PT, Rowe JM, Heal JM, Francis CW. Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution. Arch Intern Med. 1992;152(4):791-796
105. Sumida K, Ubara Y, Hoshino J, et al. Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol. 2010;29(10):1191-1194.
106. Cheema GS, Quismorio FP. Pulmonary involvement in adult-onset Still’s disease. Curr Opin Pulm Med. 1999;5(5):305-309.
107. Sari I, Birlik M, Binicier O, et al. A case of adult-onset Still’s disease complicated with diffuse alveolar hemorrhage. J Korean Med Sci. 2009;24(1):155-157.
108. Le Loët X, Daragon A, Duval C, Thomine E, Lauret P, Humbert G. Adult onset Still’s disease and pregnancy. J Rheumatol. 1993;20(7): 1158-1161.
109. Lockshin MD, Sammaritano LR. Corticosteroids during pregnancy. Scand J Rheumatol Suppl. 1998;107:136-138.
110. Fischer-Betz R, Specker C, Schneider M. Successful outcome of two pregnancies in patients with adult-onset Still’s disease treated with IL-1 receptor antagonist (anakinra). Clin Exp Rheumatol. 2011;29(6):1021-1023.
111. Berger CT, Recher M, Steiner U, Hauser TM. A patient’s wish: anakinra in pregnancy. Ann Rheum Dis. 2009;68(11):1794-1795.
112. Giampietro C, Ridene M, Lequerre T, et al. Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res. 2013;65(5):822-826.